FKFredrik Klevebro

Fredrik Klevebro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fredrik Klevebro has a total of 520 co-authors. Here are the top co-authors by number of shared publications:

  • Magnus Nilsson

    Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Surgery and Oncology, Karolinska Institutet, Stockholm, Sweden

    29 shared publications
  • Ioannis Rouvelas

    Department of Upper Abdominal Surgery, Center for Digestive Diseases, Karolinska University Hospital, Huddinge, Sweden

    19 shared publications
  • Mats Lindblad

    Division of Surgery, Department of Clinical Science Intervention and Technology (CLINTEC), Karolinska Institutet, 17177 Stockholm, Sweden

    15 shared publications
  • Magnus Nilsson

    Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden

    10 shared publications
  • Pernilla Lagergren

    Surgical Care Science, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Department of Surgery and Cancer, Imperial College London, United Kingdom

    9 shared publications
  • Richard van Hillegersberg

    Department of Surgery, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands

    9 shared publications

Latest Publications

  • The Impact of Anastomotic Leak After Esophagectomy on Long-term Survival in the Modern Era of Management (ALES Study)

    by Lorenzo Giorgi, Nadia Guidozzi, Riadh Salem, Wing K. Chou, Stijn Vanstraelen, Helena Gielen, Johnny Moons, Philippe Nafteux, Femke E. Lammes, Jelle P. Ruurda, et al.

    Objective: To determine the impact of severity of esophageal anastomotic leak (AL), standardized by ECCG grading, on long-term survival within a contemporary multicenter cohort. Summary Background data: Historical evidence suggesting AL is associated with increased recurrence and poor survival is limited by heterogeneous definitions and outdated management. This study utilizes the standardized ECCG definition to evaluate the prognostic significance of AL severity under modern perioperative protocols and endoscopic rescue strategies. Methods: An international multicenter cohort across 17 high-volume European centers. Adult patients with esophageal or junctional cancer treated with neoadjuvant CROSS or FLOT, followed by esophagectomy were included (2018–2023). Results: Out of 2905 patients, 425 (14.6%) developed an AL. AL was associated with a nearly two-fold increase in pulmonary complications (46.8% vs. 26.7%; P P P P =0.029). A lower rate of adjuvant therapy administration (33.9% vs. 43.3%; P =0.004) was observe for AL patients. No significant survival deficits were observed for leaks treated conservatively or with no-surgical intervention. Conclusions: AL requiring surgical reintervention was associated with impaired survival. This relationship identifies a high-risk clinical profile and represents a critical target for future research into strategies for clinical stabilization and risk mitigation.

  • Open Access

    Revisional surgery for delayed gastric conduit emptying after esophagectomy: the RESTORANT project

    by Marcel André Schneider, Andrew Davies, Catherine O'BRien, Cara Baker, James Gossage, Jessie Elliott, Nicola Raftery, Rakesh Ahmed, Fredrik Klevebro, Magnus Nilsson, et al.

    Summary: Delayed gastric conduit emptying (DGCE) is a debilitating functional complication after esophagectomy. Because of a lack of large-scale outcome data, this project evaluated surgical revisional strategies for refractory DGCE within a recently published mechanism-informed classification system. REvisional Surgery for delayed gasTRic conduit emptying (RESTORANT) was a multicentric, retrospective cohort study including adult patients undergoing revisional surgery for DGCE from January 1, 2015, to December 31, 2024, across 26 high-volume centers that performed 11,807 esophagectomies during this period. Patients were eligible irrespective of the date of their index esophagectomy. Interventions were stratified into Class 1 (pylorus-related, C1), Class 2 (conduit-related, C2), and Class 3 (hiatus-related/paraconduit hernia, C3), with class assigned retrospectively according to the revisional procedure performed. The primary endpoint was reported symptom resolution. A total of 196 patients underwent 263 surgical interventions for DGCE. Sustained symptom relief was comparable across all classes: C1 (47.2%), C2 (58.2%), and C3 (63.9%; P = 0.165). For C1, pyloroplasty (47.6%) and Roux-en-Y diversion (46.7%) showed similar efficacy. In C2, conduit replacement (75.0%) and remodeling (61.3%) were significantly more effective than simple mobilization (50.0%; P = 0.035). For C3, paraconduit hernia repair achieved higher resolution than crural division (65.8% vs. 47.1%). The overall complication rate was 32.7%, with significantly higher major morbidity and mortality in C2 (20.0% and 3.6%) compared with C3 (13.4% and 1.7%) and C1 (16.7% and 2.8%, P = 0.047). Multivariable analysis identified no independent predictors of surgical success but was limited by heterogeneity and sample size. RESTORANT provides the first multicentric analysis of surgical DGCE repair. While symptom resolution is achievable across all classes, C2 interventions carry increased risks. These findings may help structure future prospective audits.

  • The current management of Boerhaave syndrome—a European multicenter case-vignette study

    by Tobias Hauge, Aram Abu Hejleh, Alberto Aiolfi, Luigi Bonavina, Lena-Christin Conradi, Xavier Benoit D'JOurno, David Edholm, Jessie Elliot, Suzanne S Gisbertz, Christian Alexander Gutschow, et al.

    SUMMARY: Boerhaave syndrome is a rare surgical emergency, defined as a spontaneous perforation of the esophagus. Treatment options include endoscopic intervention and/or surgery, but the morbidity and mortality associated with Boerhaave syndrome is high. No consensus-based treatment guidelines currently exist. The aim of this study was to evaluate the diversity in treatment strategies for different clinical scenarios of Boerhaave syndrome across Europe. Forty-four surgeons from 24 different esophageal tertiary centers across nine European countries, Australia and the United Kingdom were invited to participate in this case-vignette study. Each surgeon was presented with four different cases of patients with Boerhaave syndrome and asked for their choice of initial treatment using a multiple-choice questionnaire. A multivariable regression analysis was performed to identify predictors of treatment choice. Thirty-one surgeons from 21 centers (20 in Europe across 9 countries and 1 in Australia) participated in the study. The proportion of surgeons selecting endoscopic treatment varied across the four cases (45%–84%, P < 0.01). Endoscopic treatment was associated with younger patient age (OR 0.83, 95% CI [0.75, 0.92], P < 0.01), absence of sepsis (OR 0.11, 95% CI [0.00, 0.16], P < 0.01) and increased time to treatment (OR 1.97, 95% CI [1.17, 3.31], P = 0.01). All surgeons working at Nordic centers (N = 6) exclusively opted for endoscopic treatment. We found considerable diversity in treatment strategies among surgeons presented with identical cases of patients with Boerhaave syndrome. Notably, all surgeons working at a Nordic center selected endoscopic treatment as their initial treatment strategy in all four cases.

  • The Prognostic Impact of Lymph Node Yield Upon Survival in Esophageal Cancer Broken Down by Neoadjuvant Strategy

    by Nadia Guidozzi, Wing K. Chou, Lorenzo Giorgi, Riadh Salem, Stijn Vanstraelen, Helena Gielen, Johnny Moons, Philippe Nafteux, Femke E. Lammes, Jelle P. Ruurda, et al.

    Objective: To establish a lymph node yield (LNY) change-point associated with improvements in overall survival (OS) and disease-free survival (DFS) in patients undergoing esophagectomy following neoadjuvant treatment for esophageal adenocarcinoma. Secondary endpoints include recurrence patterns and survival based on pathological staging. Summary Background Data: LNY has been associated with improved outcomes in esophageal cancer. The extent of lymphadenectomy following neoadjuvant treatment remains unclear. Methods: This multicenter European study included patients undergoing chemotherapy (CT) or chemoradiotherapy (CRT) followed by esophagectomy between 2018 and 2023. RA-CUSUM analysis identified change points between LNY and survival. Bootstrap resampling determined the optimal LNY, and multivariable Cox proportional hazards models analyzed LNY as continuous and categorical variables. A post hoc exploratory subgroup analysis was conducted in CT patients with optimal LNY compared with CRT irrespective of LNY. Recurrence patterns were assessed using the Fisher exact test. Results: A total of 2069 patients were included: 957 CT versus 1112 CRT. Median LNY was 32. CT data set: an optimal threshold of 25 nodes was identified (95% CI: 20–39). Categorical analysis using ≥25 nodes demonstrated 29% mortality reduction (HR: 0.714, P =0.0017). CRT data set: no significant LNY association across any endpoint. Continuous LNY showed a null effect ( P =0.633), and categorical analysis showed no benefit ( P =0.66). CT with ≥25 LNY had ∼44% lower mortality compared with CRT after adjustment for potential confounding variables (HR=0.563, P P =0.001). Conclusion: On the basis of this data, there is a clear survival and recurrence benefit to performing a radical lymphadenectomy with a lymph node harvest of at least 25 nodes in patients who have received CT.

  • Open Access

    Health-related quality of life comparing standard and prolonged time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer: results from the multicenter, randomized, controlled NeoRes II trial

    by Anders Holmén, Fahad Murad, Klara Nilsson, Ioannis Rouvelas, Mats Lindblad, Eva Szabo, Ingvar Halldestam, Ulrika Smedh, Bengt Wallner, Jan Johansson, et al.

    Standard time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer has historically been 4–6 weeks. Observational studies have suggested improved oncological outcomes and health-related quality of life in patients after prolonged time-to-surgery. This study aimed to investigate whether prolonged time-to-surgery is associated with improved health-related quality of life compared to the standard interval. This study is a secondary endpoint analysis within the NeoRes II trial, in which patients with locally advanced resectable esophageal cancer were randomized to either standard time-to-surgery (4–6 weeks) or prolonged time-to-surgery (10–12 weeks). The primary endpoints have been reported previously. Health-related quality of life was assessed using the EORTC QLQ-C30 and QLQ-OG25 questionnaires at time of diagnosis, preoperatively, and at 6-months and 1–5 years postoperatively. A total of 249 patients were randomized of whom 192 were available for health-related quality of life analyses, with 97 (51%) assigned to standard time-to-surgery and 95 (49%) to prolonged time-to-surgery. The groups were well-matched regarding baseline characteristics. Preoperatively, within a week of the day of surgery, patients in the prolonged time-to-surgery group reported better global quality of life, improved physical functioning, and less fatigue, coughing, dysphagia, odynophagia, pain, discomfort, and weight loss compared to those in the standard time-to-surgery group. These benefits were observed at 6 months postoperatively, but not thereafter during follow-up, where no significant differences were observed. Although prolonged time-to-surgery was associated with better preoperative health-related quality of life, no such benefits were observed postoperatively. In addition, the results from the primary endpoint analysis suggested that longer time-to-surgery was associated with worse oncological outcomes. This, together with the results of the current sub-study, strongly supports that the standard time-to-surgery of 4–6 weeks should be recommended after neoadjuvant chemoradiotherapy for esophageal cancer.

  • Open Access

    Pancreatic exocrine insufficiency after esophageal and gastric surgery: the PEGAS study

    by Maria Lampi, Patrick Maisonneuve, Ioannis Rouvelas, Mats Lindblad, Fredrik Klevebro, J. Enrique Dominguez Munoz, Jutta Keller, J.-Matthias Löhr, Magnus Nilsson, Miroslav Vujasinovic

    Pancreatic exocrine insufficiency (PEI) is a potential but under-recognized complication after upper gastrointestinal (GI) surgery, contributing to malabsorption and nonspecific GI symptoms. This prospective cohort study included adult patients undergoing esophagectomy or gastrectomy at a single tertiary referral center between March 2022 and January 2024. A total of 51 patients were included, with 34 completing full follow-up. The primary outcome was the prevalence of PEI. A secondary outcome was the effect of pancreatic enzyme replacement therapy (PERT) in patients with PEI. Among 31 patients undergoing esophagectomy, one (3.2%) was diagnosed with PEI. In contrast, PEI was identified in five (25.0%) of 20 patients after total or subtotal gastrectomy. PERT was administered in all patients with PEI. At 12-months' follow-up, clinical improvement in PEI symptoms was observed in four of six patients, while in two patients, disease progression due to cancer prevented assessment of the PERT effect. PEI is a clinically significant postoperative complication after upper GI surgery. These findings support the inclusion of pancreatic exocrine function assessment in the postoperative follow-up of gastric surgery patients, particularly those presenting with nonspecific GI symptoms and malabsorption, to enable timely diagnosis and management.


  • Top Cited Papers
    Open Access

    Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma

    by Jun Okui, Satoru Matsuda, Kengo Nagashima, Yasunori Sato, Hirofumi Kawakubo, Thomas Ruhstaller, Peter Thuss-Patience, Magnus Nilsson, Fredrik Klevebro, Lijie Tan, et al.

    Background: Although several oesophageal squamous cell carcinoma (OSCC) studies have reported no definitive overall survival (OS) differences between neoadjuvant chemoradiotherapy (NACRT) and neoadjuvant chemotherapy (NAC), the higher pCR rate with NACRT has been viewed as a potential advantage. Beyond ongoing concerns about the validity of pCR as a surrogate endpoint, it remains uncertain whether survival differs between these modalities among patients with OSCC who achieve pCR. Methods: An integrated analysis of individual patient data (IPD) from phase III trials evaluating perioperative therapies for resectable OSCC was conducted, emphasizing prognostic differences between NAC and NACRT, particularly among patients who achieved pCR. Results: IPD from seven phase III RCTs across six countries included data for 1044 patients with OSCC (83.5% male; mean age of 62.3 years). Of these patients, 605 (58.0%) received NAC and 439 (42.0%) received NACRT, with R0 resection rates of 89.6% versus 84.7% and pCR rates of 6.9% versus 34.2% respectively. Among patients who achieved pCR (192 patients), 5-year OS was 97.5% in the NAC group and 70.4% in the NACRT group, while 5-year recurrence-free survival was 80.8% and 63.7% respectively. Multivariable analysis demonstrated a significant survival advantage for NAC among patients who achieved pCR. Conclusion: Among patients who achieved pCR, postoperative outcomes varied considerably by neoadjuvant treatment modality. The markedly favourable prognosis associated with pCR after NAC suggests that these patients may represent an optimal candidate cohort for future evaluation of surgery-avoidance and watch-and-wait strategies.


  • Association of body composition, tumor-specific assessment, and patient demographics at diagnosis with 90-day and overall survival in esophageal cancer patients in a global population

    by Piers R Boshier, Suzanne S Gisbertz, George B Hanna, Fredrik Klevebro, Akihiko Okamura, C S Pramesh, John V Reynolds, Riccardo Rosati, Richard J E Skipworth, Shigeru Tsunoda, et al.

    Summary: This study seeks to define baseline variation and clinical correlates of body composition in a large international cohort of patients undergoing esophagectomy for cancer. Patients who underwent esophagectomy in 14 high-volume centers between 2007 to 2019 were eligible for inclusion. Skeletal muscle, visceral and subcutaneous adipose tissues within computer tomography images (L3 axial image), acquired routinely at diagnosis, were analyzed in accordance with a standardized protocol. In total, 1716 patients were recruited from three global regions: North America (22%), Europe (55%), and Asia (23%). Patients were predominantly male (79.5%) and adenocarcinoma was the most common histological subtype (66.6%). Characteristics significantly associated with levels of muscle and adiposity were global region, sex, age, and histological subtype (P < 0.001). Compared to adenocarcinoma, squamous cell carcinoma was associated with significantly lower levels of muscle and adiposity, a finding that was independent of global region, sex, and age using a multivariable linear regression model (P < 0.001). Reduced skeletal muscle and an excess of total adiposity at diagnosis was associated with increased 90-day mortality and reduced long-term survival. A prediction model including skeletal muscle, total adiposity at diagnosis and other tumor and patient specific variables was constructed to allow convenient survival prediction. This study adopts a standardized method to define international variation in parameters of body composition in esophageal cancer patients. Findings provide clinically relevant information regarding operative mortality and overall survival and can inform future guidelines for the use of body composition assessment in routine clinical practice.


  • Open Access

    Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials

    by Jun Okui, Satoru Matsuda, Kengo Nagashima, Yasunori Sato, Hirofumi Kawakubo, Thomas Ruhstaller, Peter Thuss-Patience, Magnus Nilsson, Fredrik Klevebro, Lijie Tan, et al.

    Background: Most recurrences after curative surgery for esophageal cancer occur within 2 years. Conventional recurrence-free survival (RFS), calculated from the time of surgery, may underestimate prognosis for patients who remain recurrence-free during the early postoperative years. This study aimed to evaluate conditional RFS and recurrence timing to inform individualized follow-up strategies. Methods: An individual patient data (IPD) analysis was conducted using randomized controlled trials (RCTs) comparing perioperative treatments for resectable esophageal or gastroesophageal junction cancer. Conditional RFS, defined as the probability of remaining recurrence-free for an additional y years given x years already survived without recurrence (RFSy|RFSx), was estimated. Results: IPD from 10 phase III and 1 phase II RCTs were analyzed (n = 2268 patients with R0 resection). In squamous cell carcinoma (SCC), RFS5|RFS0 was 47.9%, which increased to 63.0%, 72.5%, 78.2%, and 81.2% at RFS5|RFS1–4. Among patients who recurred, 58.8% of pN-positive cases recurred within 1 year and 81.7% within 2 years, compared with 42.8% and 69.9% in pN0. At baseline (RFS5|RFS0), patients with pN-positive disease or pM1 disease had worse 5-year RFS than those with pN0 or pM0 disease. However, among patients who remained recurrence-free for 4 years after surgery (RFS5|RFS4), the pattern was reversed, with advanced groups showing better subsequent 5-year RFS. Similar trends were observed in adenocarcinoma. Conclusions: Conditional RFS improves over time, particularly in advanced-stage esophageal cancer. Although advanced cases are typically monitored more intensively, findings suggest comparable follow-up intensity may be appropriate once patients remain recurrence-free for a certain postoperative period.


  • Treatment strategies for Boerhaave syndrome: multinational retrospective cohort study

    by Tobias Hauge, Aram Abu Hejleh, Alberto Aiolfi, Felix Berlth, Luigi Bonavina, Linda Brake, Lena-Christin Conradi, Xavier Benoit D’journo, David Edholm, Jessie Elliot, et al.

    Background: Boerhaave syndrome is defined as a spontaneous perforation of the oesophagus. The mainstay of treatment is resuscitation of the patient, closure of the oesophageal defect, and drainage of perioesophageal and pleural fluid collections. Whether the optimal approach is endoscopic, surgical, or conservative management remains unknown and there are no clear guidelines. The aim of this multicentre retrospective cohort study was to evaluate current treatment strategies and outcomes for Boerhaave syndrome. Methods: A multicentre retrospective analysis of data from 23 participating European tertiary centres was performed. Patients with Boerhaave syndrome treated between January 2019 and December 2023 were eligible for inclusion. The primary endpoint was the length of ICU stay and secondary endpoints included in-hospital mortality, 90-day mortality, and the length of overall hospital stay. Results: In total, 216 patients were included; 151 were men (70%), the median age was 62 (22–95) years, and 81 (40%) were treated >24 h after the start of symptoms. Seventy (32%) patients were managed endoscopically (group I), 73 (34%) were managed surgically (group II), 67 (31%) were managed using a combination of endoscopy and surgery (group III), and 6 (3%) were managed using other methods (group IV). For patients in groups I–III: the median length of ICU stay was 8 (0–67) days, with no differences between the three groups (P = 0.105); the in-hospital mortality rate and 90-day mortality rate were both 12% (P = 0.490 and P = 0.637, respectively); and the median length of overall hospital stay was 27 (range 1–193) days, with the longest stays observed in patients who received combined treatment (P = 0.032). Conclusion: This study provides a comprehensive overview of the current treatment strategies and outcomes for patients with Boerhaave syndrome in Europe.